Abstract: The problem of the present invention is to provide a patch preparation superior in the skin permeability of drugs and having good adhesive property. The present invention relates to a patch preparation containing a drug (excluding tandospirone and a pharmaceutically acceptable salt thereof), levulinic acid, and propylene glycol fatty acid ester in the adhesive layer, which is superior in the practical adhesive property and skin permeability of drugs.

Abstract: The present invention relates to a transdermal absorption preparation that can maintain a blood concentration sufficient to exert the efficacy of tandospirone, and also shows good storage stability against heat, humidity, and light. According to the present invention, a transdermal absorption preparation containing tandospirone or a pharmaceutically acceptable salt thereof, and levulinic acid, which is superior in the skin permeability of tandospirone or a pharmaceutically acceptable salt thereof in the preparation, and shows good preservation stability against heat and light can be provided.

Abstract: Provided is a transdermal absorption preparation having superior drug skin permeability, which can uniformly disperse the drug in the preparation and maintain the uniform dispersion state of the drug. A transdermal absorption preparation having a plaster layer containing a drug, a polymer and a pH adjuster, in which the aforementioned polymer contains a polymer having a particular glass transition temperature of 30° C.-200° C., and the surface of the plaster layer has a pH of 6.7-10.0.

Abstract: Provided is a transdermal absorption preparation that shows superior skin permeability of a drug and that does not easily cause cold flow. A transdermal absorption preparation having a drug-containing layer containing a drug and a polymer, wherein 50-100 wt % of the polymer in the drug-containing layer is a polymer having a glass transition temperature of 30° C.-200° C., and the drug in the drug-containing layer is in an amorphous state.

Abstract: Provided are a production method of a pregabalin-containing composition, which suppresses crystallization of pregabalin, and a pregabalin-containing composition that shows suppressed crystallization of Pregabalin. The production method of the pregabalin-containing composition of the present invention contains steps of: (1) dissolving pregabalin in an aqueous solution of an acid to prepare an aqueous solution of a salt of pregabalin; (2) mixing the aqueous solution of pregabalin salt and a hydrophilic resin to prepare a mixture thereof; and (3) concentrating the mixture; wherein the acid has an acid dissociation constant lower than that of pregabalin.

Abstract: A transdermal absorption preparation precursor 50 containing a release liner 10 containing one first valley fold part 1, one or two first mountain fold parts 2, and a first base line L1 and a second base line L2 on one side and the other side apart from the first valley fold part 1 as a line of demarcation and at an approximately equal distance from the first valley fold part 1, wherein at least one of the first base line L1 and the second base line L2 is a fold line of the first mountain fold part 2, and a drug-containing layer 3 having a center line laid on the first base line L1 and an adhesive layer 4 having a center line laid on the second base line L2 on the release liner 10.

Abstract: Provided are a production method of a pregabalin-containing composition, which suppresses crystallization of pregabalin, and a pregabalin-containing composition that shows suppressed crystallization of Pregabalin. The production method of the pregabalin-containing composition of the present invention contains steps of: (1) dissolving pregabalin in an aqueous solution of an acid to prepare an aqueous solution of a salt of pregabalin; (2) mixing the aqueous solution of pregabalin salt and a hydrophilic resin to prepare a mixture thereof; and (3) concentrating the mixture; wherein the acid has an acid dissociation constant lower than that of pregabalin.

Abstract: Provided is a transdermal absorption preparation having superior drug skin permeability, which can uniformly disperse the drug in the preparation and maintain the uniform dispersion state of the drug. A transdermal absorption preparation having a plaster layer containing a drug, a polymer and a pH adjuster, in which the aforementioned polymer contains a polymer having a particular glass transition temperature of 30° C.-200° C., and the surface of the plaster layer has a pH of 6.7-10.0.

Abstract: A transdermal absorption preparation precursor 50 containing a release liner 10 containing one first valley fold part 1, one or two first mountain fold parts 2, and a first base line L1 and a second base line L2 on one side and the other side apart from the first valley fold part 1 as a line of demarcation and at an approximately equal distance from the first valley fold part 1, wherein at least one of the first base line L1 and the second base line L2 is a fold line of the first mountain fold part 2, and a drug-containing layer 3 having a center line laid on the first base line L1 and an adhesive layer 4 having a center line laid on the second base line L2 on the release liner 10.

Abstract: Provided is a transdermal absorption preparation that shows superior skin permeability of a drug and that does not easily cause cold flow. A transdermal absorption preparation having a drug-containing layer containing a drug and a polymer, wherein 50-100 wt % of the polymer in the drug-containing layer is a polymer having a glass transition temperature of 30° C.-200° C., and the drug in the drug-containing layer is in an amorphous state.